

Development and Function of Diabetogenic T-cells in B-cell–Deficient Nonobese Diabetic Mice

Priscilla P.L. Chiu,^{1,2,4} David V. Serreze,⁵ and Jayne S. Danska^{1,3,4}

Insulin-dependent diabetes (type 1 diabetes) in the NOD mouse is a T-cell–mediated autoimmune disease. However, B-cells may also play a critical role in disease pathogenesis, as genetically B-cell–deficient NOD mice (NOD.μMT) have been shown to be protected from type 1 diabetes and to display reduced responses to certain islet autoantigens. To examine the requirements for B-cells in the development of type 1 diabetes, we generated a B-cell–naive T-cell repertoire by transplantation of NOD fetal thymuses (FTs) into NOD.scid recipients. Surprisingly, these FT-derived NOD T-cells were diabetogenic in 36% of NOD.scid recipients, despite the absence of B-cells. In addition, T-cells isolated from NOD.μMT mice were diabetogenic in 22% of NOD.scid recipients. Together, these results indicate that B-cells are not an absolute requirement for the generation or effector function of an islet-reactive T-cell repertoire in NOD mice. We suggest that conditions favoring rapid lymphocyte expansion can reveal autoreactive T-cell activity and precipitate disease in genetically susceptible individuals. *Diabetes* 50:763–770, 2001

Type 1 diabetes in the NOD mouse is characterized by the infiltration of T-cells and antigen (Ag)-presenting cells (APCs) into the pancreatic islets of Langerhan (insulinitis), resulting in the eventual destruction of insulin-producing pancreatic β-islet T-cells (1). Diabetes pathogenesis in NOD mice is T-cell–dependent; adoptive transfer of splenic T-cells from NOD donors into irradiated NOD or NOD mice congenic for the *scid* mutation (NOD.scid) causes type 1 diabetes in the recipients (2,3). It has been shown that B-cells are not required at the effector stage of NOD type 1 diabetes, as T-cells from diabetic NOD donors transfer type 1 diabetes to B-cell–depleted NOD neonates (4). However, recent evidence suggests that B-cells play an important role in the development of autoreactivity in NOD type 1 diabetes;

NOD mice rendered B-cell deficient by antibody treatment are protected from the development of insulinitis and diabetes (5–8). Using a genetic approach, several groups have shown that NOD mice homozygous for a germline mutation that disables production of membrane-bound Igμ (μMT), resulting in maturational arrest of B-cell development, affords protection against type 1 diabetes (6,8). However, the mechanism, or mechanisms, by which B-cells affect type 1 diabetes pathogenesis is unclear. B-cells could influence autoimmune disease through autoantibody production or as APCs involved in the selection or activation of autoreactive T-cells. High titers of anti-insulin and anti-GAD autoantibodies are found in prediabetic NOD mice and diabetic humans (9–11), but in contrast to T-cells, autoantibodies fail to transfer disease in NOD mouse models. When activated, B-cells become competent APCs (12) that may capture and present islet T-cell Ags to T-cells (13,14). In addition, Ag presentation by B-cells in the thymus could affect selection of the T-cell repertoire (15). Thus, there are several mechanisms by which B-cells could affect susceptibility to and onset of type 1 diabetes.

We present an independent approach to analyze the requirement(s) for B-cells in the development and function of an islet-reactive T-cell repertoire in NOD mice. To study the function of an NOD T-cell repertoire in the absence of B-cells, we transplanted NOD.NON-*Thy1*^a (NOD.*Thy1*^a) fetal thymuses (FTs) into NOD.scid mice, resulting in reconstitution of the recipients with NOD-derived *Thy1*^a-marked T-cells. Surprisingly, NOD.scid mice reconstituted with NOD FT-derived T-cells developed type 1 diabetes. Parallel experiments using donor T-cells from genetically B-cell–deficient NOD.μMT mice showed that T-cells from these mice were also able to transfer diabetes to a low frequency of NOD.scid recipients. Rather, our results indicate that B-cells are not absolutely required for the development of an autoimmune repertoire or for the effector function against islet T-cells. These results indicate that autoreactive T-cells generated in B-cell–deficient NOD animals can become pathogenic under conditions of T-cell reconstitution and expansion in lymphoid-deficient hosts.

From the ¹Program in Developmental Biology, the Hospital for Sick Children Research Institute; the Departments of ²Surgery and ³Immunology and the ⁴Institute of Medical Science, University of Toronto, Ontario, Canada; and the ⁵Jackson Laboratory, Bar Harbor, Maine.

Address correspondence and reprint requests to Dr. Jayne Danska, The Hospital for Sick Children Research Institute, 555 University Ave., Toronto, Ontario, Canada, M5G 1X8. E-mail: danska@sickkids.on.ca.

Received for publication 28 August 2000 and accepted in revised form 22 December 2000.

Ab, antibody; Ag, antigen; APC, Ag-presenting cell; BSA, bovine serum albumin; Cμ2A, Ig Cμ 3'-primer; DC, dendritic cell; FACS, fluorescence-activated cell sorter; FITC, fluorescein isothiocyanate; FT, fetal thymus; Igh, Ig heavy chain; KLH, keyhole limpet hemocyanin; LN, lymph node; mAb, monoclonal antibody; MHC, major histocompatibility complex; μMT, Igμ constant transmembrane region; PBL, peripheral blood lymphocyte; PBS, phosphate-buffered saline; PI, propidium iodide; RT-PCR, reverse transcriptase–polymerase chain reaction; VHALL, Ig Vh 5'-primer.

RESEARCH DESIGN AND METHODS

Mice used in these studies were maintained in a pathogen-free facility at the Hospital for Sick Children, Toronto, Ontario, Canada, in which the incidence of diabetes was 80–85% for NOD females and 10–15% for NOD males at 30 weeks of age. NOD.*Thy1*^a congenic mice were obtained from Jackson Laboratories (Bar Harbor, ME) and bred in our facility. These mice were maintained by brother-sister mating at N8 backcross to NOD. The incidence of diabetes in our NOD.*Thy1*^a colony was 60–75% for females and 5–10% for males at 30 weeks of age. B-cell–deficient NOD.μMT mice were generated as described (8) and used at the N10 backcross to NOD. NOD.scid mice (Jackson Laboratories) were at the N10 backcross to NOD.




FIG. 1. Reconstitution of NOD.scid mice with $Thy1^{a+}$ FT-derived T-cells. T-cells from the NOD. $Thy1^a$ NOD congenic strain express the $Thy1^a$ allotype, whereas NOD.scid T-cell precursors express $Thy1^b$. NOD. $Thy1^a$ females were bred with plug date designated as day 1. Four-week-old NOD.scid recipients were transplanted with 4–6 lobes of day-15 NOD. $Thy1^a$ FTs under the left kidney capsule (RESEARCH DESIGN AND METHODS). Two weeks posttransplant, the NOD.scid FT recipients were examined for FT-derived T-cell reconstitution in the peripheral blood by flow cytometry using FITC-conjugated anti- $Thy1^a$ mAb (19XE5). Dead cells were excluded by PI staining. **A:** A kidney from a transplanted NOD.scid recipient 4 weeks posttransplant, showing the NOD. $Thy1^a$ thymus tissue under the kidney (\blacktriangleright). **B:** A representative FACS experiment showing the percentage of T-cells ($Thy1^{a+}$) in the PBL of a 4-week-old NOD. $Thy1^a$ mouse and a NOD.scid recipient of NOD. $Thy1^a$ FT. Compared with the PBL of NOD. $Thy1^a$ control, the NOD.scid FT recipient was successfully reconstituted with $Thy1^a$ FT-derived T-cells. **C:** Generation of NOD FT-derived B-cell-naïve T-cells in NOD.scid recipients. The experimental protocol for transplantation of NOD. $Thy1^{a+}$ FT into primary NOD.scid recipients followed by adoptive transfer of FT-derived T-cells into secondary NOD.scid recipients can be found in RESEARCH DESIGN AND METHODS.

FT transplant. Embryonic day 15 (coitus plug = day 1) NOD. $Thy1^a$ fetal thymuses were isolated, and four to six fetal lobes were transplanted under the left kidney capsule of 3- to 4-week-old NOD.scid recipients (Fig. 1A). Reconstitution of peripheral blood lymphocytes (PBL) with $Thy1^{a+}$ FT-derived T-cells (FT-T-cells) was assessed 2 weeks postoperatively. After red cell lysis, PBLs were stained with fluorescein isothiocyanate (FITC)-conjugated anti- $Thy1^a$ monoclonal antibody (mAb) (19XE5) and anti- $Thy1^b$ mAb (53-2.1) for analysis on the FACSCalibur (Becton Dickinson, Mountain View, CA). Dead cells were excluded by propidium iodide (PI) staining. Fluores-

cence-activated cell sorter (FACS) analysis of 5×10^3 cells was performed to assess reconstitution by the FT-derived T-cells (Fig. 1B). Data analyses were performed using CellQuest software (Becton Dickinson).

Adoptive transfer of $Thy1^{a+}$, FT-derived, and NOD. μ MT T-cells. FT recipients were killed 7 weeks posttransplant, and peripheral lymph nodes (LNs) and spleens were isolated. LN and spleen cell suspensions were prepared and immunodepleted with anti-class II major histocompatibility complex (MHC) (10-2.16), anti-B220 (RA3-6B2), and anti-Mac-1 (M1/70) mAb, and magnetic beads (PerSeptive Biosystems, Framingham, MA). NOD.scid

immature T-cell precursors were depleted using anti-*Thy1^b* (53-2.1) mAb. Ten to twenty million *Thy1^{a+}* FT-T-cells were injected intraperitoneally into each NOD.*scid* recipient (secondary recipients). Twenty million splenic T-cells from 6-week-old NOD. μ MT mice were purified by immunodepletion with M1/70 and 10-2.16 and transferred into NOD.*scid* recipients. Similarly, 2×10^7 T-cells from 6-week-old NOD.*Thy1^a* mice, enriched by immunodepletion using M1/70, RA3-6B2, 10-2.16, and magnetic beads, were transferred into NOD.*scid* recipients as positive controls. NOD.*scid* recipients injected with phosphate-buffered saline (PBS) served as negative controls. All NOD.*scid* recipients were monitored for glycosuria weekly using Tes-Tape (Eli Lilly, Toronto) for 22 weeks postadoptive transfer. Recipients were scored as diabetic if they were positive for glycosuria by Tes-Tape on 2 consecutive days. Recipients that remained euglycemic at 22 weeks postadoptive transfer were killed, and their pancreata were isolated for histological examination.

Analysis of FT-T-cell recipients for the presence of mature B-cells. NOD.*scid* recipients of FT-T-cells were assessed for the presence of B-cells using flow cytometry and reverse transcriptase-polymerase chain reaction (RT-PCR). For flow cytometry, 1×10^6 LNs and spleen cells were stained with FITC-conjugated anti-B220 mAb (RA3-6B2) and biotinylated anti-CD19 mAb (1C3; Pharmingen). Stained cells were analyzed on the FACSCalibur. Ten thousand live (PI-excluding) cells were collected for each recipient. For RT-PCR analysis, RNA was prepared from spleen cells using Trizol (Gibco BRL, Burlington, ON, Canada). RNA isolated from 1×10^6 cells were used for the synthesis of cDNA using Superscript II reverse transcriptase (Life Technologies, Burlington ON, Canada), and NOD spleen RNA was used in mock (minus RT) control reactions. A PCR strategy was used to detect V(D)J recombination at the Ig heavy chain (Igh) locus (16). A degenerate Ig Vh 5'-primer (VHALL) and an Ig C μ 3'-primer (C μ 2A) were used to amplify the cDNA as previously described (16). PCR products of 700 bp reflected transcription of the rearranged Igh locus. PCR products were separated on 0.8% agarose gels and transferred to nylon membranes (ZetaProbe; BioRad Laboratories, Hercules, CA). Southern blot hybridization analysis was performed using an Ig μ constant region probe (17). Images were collected on a phosphorscreen (Molecular Dynamics, Sunnyvale, CA) and analyzed by Image-Quant software (Molecular Dynamics). β -actin PCR controls were performed simultaneously for each cDNA sample. Assay sensitivity was determined by titrations of cDNA from 10×10^6 to 1×10^6 NOD spleen cells.

Histological examination of pancreata of adoptive transfer recipients. Pancreata from all recipients were evaluated by histological examination of sections as described (18). Insulinitis was scored on a scale of 0–4, where 0 represents the absence of insulinitis and 4 represents severe invasive insulinitis obscuring the islet. Immunohistochemistry of 8- μ m serial sections was used to detect B220⁺ B-cells and *Thy1^{a+}* or *Thy1^{b+}* T-cells. Pancreatic sections were fixed with ethanol and blocked with 50 mg/ml bovine serum albumin (BSA). Pancreatic sections were incubated in 1% peroxide to inhibit endogenous peroxidase activity. The slides were washed with PBS + 1% BSA (PBS + BSA) before staining with biotinylated anti-B220 (RA3-6B2) mAb (Pharmingen), anti-*Thy1^a* (19XE5) mAb, and anti-*Thy1^b* (53-2.1) mAb (Pharmingen). The sections were rinsed with PBS + BSA before incubation with streptavidin-conjugated peroxidase followed by chromagen stain (Sigma Chemicals, St. Louis, MO). The slides were counterstained with hematoxylin and rinsed in PBS + BSA.

RESULTS

Generation of B-cell-deficient NOD mice by FT transplantation. FT transplantation was used to generate a B-cell-naïve T-cell repertoire of NOD origin (19). Thy-muses were removed from embryonic day 15 NOD.*Thy1^a* fetuses and transplanted under the kidney capsule of 3- to 4-week-old NOD.*scid* recipients (primary recipients) (Fig. 1A). The procedure resulted in good reconstitution of NOD.*scid* recipients with *Thy1^{a+}* FT-derived T-cells as early as 2 weeks posttransplant (Fig. 1B). By 7 weeks posttransplant, these primary NOD.*scid* hosts were fully reconstituted with FT-derived T-cells. *Thy1^{a+}* FT-T-cells were recovered from the primary recipients and transferred into secondary NOD.*scid* hosts (Fig. 1C). Parallel experiments were performed to compare the diabetogenic potential of the NOD FT-T-cells with age-matched T-cells from unmanipulated NOD donors. Mice homozygous for a targeted mutation disrupting the Ig μ constant transmembrane region (μ MT) are genetically B-cell deficient (20). On the NOD

background, this mutation (NOD. μ MT) was previously reported to significantly reduce diabetes frequency (8). Here we performed parallel experiments to compare the diabetogenic potential of NOD. μ MT T-cells with NOD FT-derived T-cells transferred into NOD.*scid* recipients (Fig. 1C). This approach enabled direct comparison of the diabetogenic potential of normal, with two different sources of B-cell-naïve NOD T-cells. In both of the experimental groups, the NOD FT-derived and NOD. μ MT T-cell repertoire developed in the absence of B-cells and was assessed for autoimmune effector function in a B-cell-deficient environment.

B-cell deficiency in NOD.*scid* FT-T-cell recipients. Interpretation of these experiments depended on verification of B-cell deficiency in NOD.*scid* recipients of NOD FT-derived and NOD.*scid* (21) T-cells. Rare B-cell precursors are present in day-15 FT, but their development has been found to require addition of exogenous cytokines (22). In addition, rare Ig⁺ B-cells have been observed in aged CB-17.*scid* (23–25) and NOD.*scid* (21) mice, providing another potential source of B-cell contamination in the NOD FT-derived T-cell-reconstituted animals. We used two approaches to test for B-cells in FT-derived T-cell-reconstituted primary and secondary NOD.*scid* recipients (Fig. 1C). Two-color flow cytometric analysis of primary and secondary NOD.*scid* recipients of FT-derived T-cells was performed using antibodies to the B-cell markers B220 and CD19. B220⁺CD19⁺ cells were undetectable in the LNs and the spleens of both primary and secondary NOD.*scid* FT-T recipients. Indeed, these profiles were indistinguishable from age-matched unmanipulated NOD.*scid* mice (Fig. 2A). As an independent assessment, we used an RT-PCR approach followed by Southern blot hybridization to detect Ig μ mRNA transcripts resulting from VDJ μ recombination in the splenocytes of secondary NOD.*scid* FT-derived T-cell recipients (16). Titration experiments showed that this technique could detect Ig μ transcripts in as few as 10 spleen cell equivalents from normal NOD animals (Fig. 2B, panel i). Under these experimental conditions, we could not detect full-length Ig VDJ μ -containing transcripts in the splenocytes of NOD.*scid* FT-T-cell recipients (Fig. 2B, panel ii). Occasionally, we observed Ig μ amplicons in NOD.*scid* mice (Fig. 2B, panel ii), which is consistent with reports that V(D)J recombination occurs with low frequency in *scid* mice (25,26). Together, the flow cytometry and PCR analyses strongly suggest that both primary and secondary NOD.*scid* mice harboring NOD FT-derived T-cells were indeed B-cell deficient.

Incidence of insulinitis and diabetes in NOD.*scid* T-cell recipients. NOD.*scid* recipients of normal NOD, NOD FT-derived, and NOD. μ MT T-cells were followed for 22 weeks postadoptive transfer to assess diabetes onset. A total of 66% of NOD.*scid* recipients of 6-week-old NOD T-cells became diabetic within this observation period (Table 1, Fig. 3). Unexpectedly, 40% of the recipients of NOD FT-derived T-cells and 22% of the recipients of NOD. μ MT T-cells became diabetic during the observation period (Table 1, Fig. 3). These results suggest that B-cell-naïve NOD T-cells created either by FT transplantation into NOD.*scid* recipients or by introgression of the μ MT mutation onto the NOD background have the potential to cause diabetes in NOD.*scid* hosts.




FIG. 2. The absence of B-cells in NOD.scid recipients of FT or FT-derived T-cells. **A:** LNs from 20-week-old NOD.Thy1^a, NOD.scid, primary NOD.scid FT recipients, and secondary NOD.scid FT-derived T-cell recipients were prepared into cell suspensions and stained with FITC-conjugated anti-B220 (RA3-6B2) and biotinylated anti-CD19 (1C3). Dead cells were excluded by PI staining. Diabetic secondary NOD.scid FT-derived recipients were also analyzed for the presence of B-cells by flow cytometry. In the NOD.scid mouse, B220⁺CD19⁺ cells constituted <0.1% of the LN population. In NOD.scid recipients of primary NOD FT and secondary NOD FT-derived T-cells, B220⁺CD19⁺

TABLE 1

Diabetes incidence in NOD.scid recipients of NOD, NOD.μMT, and NOD FT-derived T-cells

T-cell donor	Incidence of diabetes	Time to diabetes average (days)
6-week-old NOD	67 (6 of 9)	114 (96–149)
6-week-old FT-derived NOD.Thy1 ^a	36 (8 of 22)	115 (94–182)
6-week-old NOD-μMT	22 (2 of 9)	130 (126–134)
PBS-control	0 (0 of 6)	

Data are % (*n*) or means (range).

Histological examination was performed on the pancreata of all NOD.scid T-cell recipients either at the time of diabetes onset or at 22 weeks post-T-cell transfer, whichever came first. Diabetic recipients of either NOD FT-derived or NOD.μMT T-cells displayed severe invasive insulinitis (data not shown). Using immunohistochemical staining, the islet-infiltrating cells in these animals were of donor origin (Thy1^{a+}), and neither Thy1^{b+} nor B220⁺ cells were detected in the lesions (data not shown). NOD.scid recipients of NOD FT-derived or NOD.μMT T-cells that remained euglycemic 22 weeks after adoptive transfer were also examined for pancreatic infiltration. Among these mice, 2 of 7 recipients of NOD.μMT T-cells and 5 of 14 recipients of NOD FT-derived T-cells had mean insulinitis scores >1.5; this is suggestive of progression toward invasive insulinitis (Fig. 4). Some of these animals might have become diabetic over a longer observation period after T-cell transfer. Altogether, 13 of 22 (59%) recipients of NOD FT-derived T-cells and 4 of 9 (44%) recipients of NOD.μMT T-cells demonstrated invasive insulinitis and/or diabetes 22 weeks after adoptive transfer, despite the absence of B-cells.

DISCUSSION

Several groups have reported that B-cells are critical for the development of NOD insulinitis and type 1 diabetes (6–8). A suggested mechanism of this effect is that NOD B-cells are uniquely capable of capturing and presenting islet Ags associated with NOD type 1 diabetes in the context of the MHC class II molecules (13,14,27). Although NOD.μMT mice are protected from type 1 diabetes, some animals became diabetic with the same kinetics as B-cell-sufficient NOD littermates, albeit with a much lower incidence (28). In this report, we present evidence that insulinitis and diabetes can develop in the absence of NOD B-cells, and we suggest that under some conditions macrophages (Mφs) and dendritic cells (DCs) are sufficient to select an autoreactive T-cell repertoire and to precipitate autoimmune disease in NOD mice.

cells were not detectable by flow cytometry. **B:** RNA was isolated from 1×10^6 splenocytes from age-matched NOD, NOD.scid, and diabetic secondary NOD.scid FT-T recipients and reverse transcribed into cDNA. To detect Igμ gene transcriptional product, a degenerate VHALL 5' primer and a 3' primer, Cμ2A, in the constant region of the Igh were used to amplify the cDNA. PCR products of 700 bp represent mRNA resulting from VDJ gene rearrangement at the Igh locus. β-actin controls were performed simultaneously for each cDNA sample. Southern blot analysis of the VHALL-Cμ2A PCR products was performed using ³²P-labeled Igμ probe. **B, panel i:** Sensitivity of the RT-PCR assay as indicated by the dilution of cDNA ranging from 5×10^4 to 10 spleen cell equivalents. **B, panel ii:** Assay of Igμ mRNA from 5×10^4 cell equivalents of NOD, NOD.scid, and secondary NOD.scid FT-T recipients.




FIG. 3. Diabetes incidence in recipients of NOD, NOD FT-T, and NOD.μMT T-cells. NOD.*scid* recipients of T-cells from 6-week-old NOD ($n = 9$) (□), NOD.*Thy1^a* FT-T ($n = 22$) (◇), NOD.μMT ($n = 9$) (○) donors, or PBS treatment ($n = 6$) (△) were monitored for glycosuria for 22 weeks postadoptive transfer.

There are multiple potential explanations for the difference observed in the NOD FT-derived and NOD.μMT T-cell transfer models compared with previously published results in NOD.μMT and anti-Igμ-treated NOD mice. Previously, gene-targeted disruption of the membrane-bound form of the IgM (μMT) B-cell receptor (6,8,28) or anti-Igμ treatment (5,7) was used to generate




FIG. 4. Histological analysis of insulinitis in euglycemic NOD.*scid* recipients of NOD, NOD FT-derived, and NOD.μMT-derived T-cells. Pancreatic sections of NOD.*scid* recipients that remained euglycemic 22 weeks after adoptive transfer were examined for insulinitis (RESEARCH DESIGN AND METHODS). Data are shown for NOD.*scid* recipients of NOD FT-derived ($n = 14$) and NOD.μMT T-cells ($n = 7$). A total of 8-μ serial sections were made at 100-μ intervals, and 30 islets were examined in each recipient. For each islet, a score from 0 to 4 was given to indicate insulinitis severity (0 = absence of insulinitis and 4 = severe and complete invasive insulinitis). An average insulinitis score was calculated for each recipient. The bar represents the mean insulinitis score from the average scores of each cohort. Note that the histogram plot does not resolve animals in the same group that had very similar insulinitis scores, as shown by the individual circles, so the designated number of animals per group exceeds the number of circles.

B-cell-deficient NOD mice. The μMT mutation was bred from a mixed 129/Sv × C57BL/6 background onto the NOD background. As a result, protective alleles at insulin-dependent diabetes loci (*Idd*) could have been transferred along with the μMT mutation, decreasing disease susceptibility in NOD.μMT mice. We do not favor this explanation, because the diabetes protection in NOD.μMT mice was demonstrated after the sixth backcross (N7) generation, and these mice were typed for microsatellite markers linked to 15 of the 19 known *Idd* susceptibility loci (8). The NOD.μMT animals used in the current study were products of three additional back-crosses (N10) and were typed for additional markers: D3Mit100 near the *Idd10*, 17, and 18 region and D10Mit87 near the *IFNγR* gene (data not shown) recently reported to be linked to a diabetes protection locus in 129/Sv mice (29). Diabetes incidence in NOD.μMT mice housed at the Jackson Laboratories from 1996 to the present is low, but detectable (3–5%) (D.V. Serreze, unpublished data); this is consistent with the idea that this mutation provides substantive but not absolute protection from diabetes. In independent studies, in vivo treatment with anti-Igμ Abs has suggested that removal of B-cells in the neonatal period protects NOD mice against type 1 diabetes. Furthermore, treatment of neonatal NOD mice with natural Ig alters diabetes development, although the mechanism of protection is unclear (30). In both instances, in vivo Ab treatment may provoke immunological modulations in addition to clearance or alteration of B-cell function. In contrast, our approach using NOD FT-derived T-cells did not require manipulation of the NOD genome or in vivo Ab treatments and thereby avoided effects independent of B-cell depletion.

T-cell responses to a variety of foreign Ags are poor in NOD.μMT homozygous mice compared with NOD.μMT⁺ and NOD controls, suggesting that the mutation causes global rather than autoantigen-specific effects on cellular immunity. For example, C57BL/6-μMT mice have reported defects in delayed-type hypersensitivity responses to in vivo challenges with pathogens such as *Chlamydia* (31), *Mycobacteria* (32), and *Listeria* (33). Furthermore, priming of NOD.μMT mice with keyhole limpet hemocyanin (KLH) generated lower recall responses compared with NOD T-cells (27), although T-cell responses to KLH were readily observed in C57BL/6-μMT mice (34). These data suggest that NOD.μMT T-cell responses to a broad array of antigens may be significantly different from the NOD parental strain. If this is indeed the case, the diabetes protection observed in NOD.μMT mice may reflect a general impairment in T-cell responses in addition to a specific requirement for B-cells in generation and function of diabetogenic T-cells.

A fundamental feature of autoimmune diabetes susceptibility may be the extent and the kinetics of self-reactive T-cell proliferation and apoptosis in peripheral tissues. Indeed, NOD T-cells demonstrate enhanced proliferation (35) and resistance to apoptosis (36–39) compared with T-cells from nondiabetes-prone strains. Based on these findings, our adoptive transfer approach into NOD.*scid* recipients may favor the expansion of islet-reactive NOD FT-derived and NOD.μMT T-cells precipitating the development of type 1 diabetes. NOD.*scid* mice are excellent adoptive transfer recipients because of the absence of

mature lymphocytes, depressed natural killer cell cytolytic activity, and the absence of circulating complement (21). The paucity of mature lymphocytes in NOD.*scid* mice permits rapid expansion of donor T-cells. We have shown that FT-derived T-cells mature and disseminate in the lymphoid organs of primary and secondary NOD.*scid* recipients. Perhaps the T-cell expansion caused by repopulation of the NOD.*scid* host is permissive for expansion and activation of autoreactive T-cells. Consistent with this idea, we show that the autoreactive T-cells in NOD. μ MT mice that rarely cause diabetes in situ have heightened pathogenic potential when transferred into the lymphopenic NOD.*scid* microenvironment.

Multiple independent lines of evidence support this reasoning in the context of autoimmune diabetes. The first comes from analyses of the Diabetes-Prone BioBreeding (DP-BB) rat and the related DR-BB strain. In DP-BB rats, a locus (*iddm1*) conferring severe T-cell lymphopenia (*lyp*) is required for spontaneous diabetes, but the *lyp* gene has not yet been identified (40,41). Interestingly, reconstitution of DP-BB animals with histocompatible T-cells from normal rats affords partial protection from diabetes, highlighting the direct contribution of T-cell lymphopenia to diabetes development (42,43). Although the nonlymphopenic DR-BB strain is diabetes resistant under normal conditions, interventions that produce lymphopenia, such as ionizing radiation and cyclophosphamide, induce type 1 diabetes in this strain (44,45). Recent studies demonstrate that the diabetogenic potential of the DR-BB T-cell repertoire is revealed after adoptive transfer of DR-BB T-cells into thymectomized and irradiated DP-BB recipients (46). Collectively, these studies demonstrate that the pathogenic potential of autoreactive T-cells in the BB rat is enabled when these cells are placed in a lymphopenic environment. Similar to the contribution of *lyp* to diabetes in the BB rat, diabetes development in NOD mice is dramatically accelerated after recovery from cyclophosphamide-induced lymphopenia (47,48). A particularly revealing example of the cyclophosphamide effect was reported in lethally irradiated NOD mice reconstituted with 50:50 mixed bone marrow isolated from MHC class II-deficient (NOD.I-A β ^{-/-}) and B-cell-deficient (NOD. μ MT) mice (13). The resultant bone marrow chimeras were not spontaneously diabetic, a finding the authors argue reflects the absence of MHC class II-expressing B-cells. However, these mice have insulinitis, and cyclophosphamide treatment caused rapid diabetes onset. Thus, the absence of MHC class II-expressing B-cells does not preclude the production and destructive function of an islet-reactive T-cell repertoire. Rather, these T-cells are generated in the absence of MHC class II-expressing B-cells and are pathogenic when conditions favor their expansion. We also report a high frequency of diabetes in 35-week-old NOD. μ MT mice after cyclophosphamide treatment, underscoring the pathogenic potential of NOD T-cells that developed in the absence of B-cells. Considering the evidence from the BB rat and the cyclophosphamide-treated NOD mice, together with the data provided here, we suggest that conditions that favor extensive lymphocyte expansion can reveal autoreactive T-cells and precipitate disease in genetically susceptible individuals. This idea has important implications for broad T-cell-depleting therapies, which warn

that the rebound effect of these agents may aggravate rather than alleviate autoimmune reactivity.

Previous reports suggest that NOD B-cells are uniquely capable of capturing and presenting specific islet Ags to islet-reactive NOD T-cells (13,14,27). However, we observed the development of type 1 diabetes in 36 and 22% of NOD.*scid* recipients of NOD FT-derived or NOD. μ MT T-cells, respectively. Although these diabetes incidences are reduced compared with NOD.*scid* recipients of normal NOD T-cells, our results suggest that myeloid APCs, such as M ϕ s and DCs, are sufficient to select, activate, and sustain autoreactive T-cells. In our study, the absence of lymphocytes in the NOD.*scid* hosts may have enhanced the density of myeloid APCs and increased their effectiveness as stimulators of autoreactive T-cells. M ϕ s and mature DCs express high levels of costimulatory molecules (49,50) and are clearly implicated in type 1 diabetes pathogenesis. For example, the depletion of M ϕ s from NOD mice transgenic for a diabetogenic T-cell receptor protected ectopic islet grafts from destruction and blocked the capacity of the T-cell receptor transgenic T-cells to transfer disease into NOD.*scid* recipients (51). M ϕ s and DCs infiltrate NOD and NOD.*scid* islets before and independent of T- and B-cells (18,52–54) and produce proinflammatory mediators tumor necrosis factor- α and γ -interferon and nitric oxide that contribute to type 1 diabetes (55). Conversely, depletion of NOD M ϕ s prevents the onset of type 1 diabetes (51,52,56,57), and in other rodent models of type 1 diabetes, DCs and M ϕ s are necessary and sufficient to cause diabetes (58,59). Together, these data indicate that M ϕ s and DCs are also critical APCs for diabetes development and can suffice to select and activate an islet-reactive T-cell repertoire. However, the presence of B-cells likely contributes to a greater efficiency of T-cell activation and expansion, potentiating diabetes development. For these reasons, therapeutic strategies for the prevention of type 1 diabetes in susceptible individuals will likely be more efficacious when directed toward multiple types rather than B-cells alone.

ACKNOWLEDGMENTS

This work was supported by grants from the Canadian Diabetes Association in honor of Madelen Francis Armstrong, the Juvenile Diabetes Foundation International, and the Medical Research Council of Canada. J.S.D. is a Research Scientist of the National Cancer Institute of Canada. P.P.L.C. is the recipient of a Juvenile Diabetes Foundation International Postdoctoral Fellowship.

We thank Philippe Poussier, Gillian Wu, Joan Wither, and Cynthia Guidos for their technical assistance and comments on this manuscript.

REFERENCES

1. Foster DW: Diabetes mellitus. In *Harrison's Principles of Internal Medicine*. 11th ed. E. Braunwald, Ed. New York, McGraw-Hill, 1983, p. 1778
2. Wicker LS, Miller BJ, Mullen Y: Transfer of autoimmune diabetes mellitus with splenocytes from nonobese diabetic (NOD) mice. *Diabetes* 35:855–860, 1986
3. Christianson SW, Shultz LD, Leiter EH: Adoptive transfer of diabetes into immunodeficient NOD.*scid/scid* mice: relative contributions of CD4⁺ and CD8⁺ T-cells from diabetic versus prediabetic NOD.NON-*Thy-1*^a donors. *Diabetes* 42: 44–55, 1993
4. Bendelac A, Boitard C, Bendossa P, Bazin H, Bach J-F, Carnaud C: Adoptive T-cell transfer of autoimmune nonobese diabetic mouse diabetes

- does not require recruitment of host B lymphocytes. *J Immunol* 141:2625–2628, 1988
5. Forsgren S, Andersson A, Hillorn V, Soderstrom A, Holmberg D: Immunoglobulin-mediated prevention of autoimmune diabetes in the non-obese diabetic (NOD) mouse. *Scand J Immunol* 34:445–451, 1991
 6. Akashi T, Nagafuchi S, Anzai K, Kondo S, Kitamura D, Wakana S, Ono J, Kikuchi M, Niho Y, Watanabe T: Direct evidence for the contribution of B-cells to the progression of insulinitis and the development of diabetes in nonobese diabetic mice. *Intern Immunol* 9:1159–1164, 1997
 7. Noorchashm H, Noorchashm N, Kern J, Rostami SY, Barker CF, Naji A: B-cells are required for the initiation of insulinitis and sialitis in nonobese diabetic mice. *Diabetes* 46:941–946, 1997
 8. Serreze DV, Chapman HD, Varnum DS, Hanson MS, Reifsnyder PC, Richard SD, Fleming SA, Leiter EH, Shultz LD: B lymphocytes are essential for the initiation of T-cell-mediated autoimmune diabetes: analysis of a new “speed congenic” stock of NOD.Igμ null mice. *J Exp Med* 184:2049–2053, 1996
 9. Tisch R, Yang X, Singer SM, Liblau RS, Fugger L, McDevitt HO: Immune response to glutamic acid decarboxylase correlates with insulinitis in non-obese diabetic mice. *Nature* 366:72–75, 1993
 10. Kaufman DL, Clare-Salzer M, Tian J, Forsthuber T, Ting GSP, Robinson P, Atkinson MA, Sercarz EE, Tobin AJ, Lehmann PV: Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. *Nature* 366:69–72, 1993
 11. Bingley PJ: Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA⁺ relatives: the ICARUS data set. *Diabetes* 45:1720–1728, 1996
 12. Constant S, Schweitzer N, West J, Ranney P, Bottomly K: B lymphocytes can be competent antigen-presenting cells for priming CD4⁺ T-cells to protein antigens in vivo. *J Immunol* 155:3734–3741, 1995
 13. Noorchashm H, Lieu YK, Noorchashm N, Rostami SY, Greeley SA, Schlachterman A, Song HK, Noto LE, Jevnikar AM, Barker CF, Naji A: I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T-cell tolerance to islet beta cells of nonobese diabetic mice. *J Immunol* 163:743–750, 1999
 14. Falcone M, Lee J, Patstone G, Yeung B, Sarvetnick N: B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice. *J Immunol* 161:1163–1168, 1998
 15. Mazda O, Watanabe Y, Gyotoku J, Katsura Y: Requirement of dendritic cells and B-cells in the clonal deletion of Mls-reactive T-cells in the thymus. *J Exp Med* 173:539–547, 1991
 16. Pennycook JL, Chang Y, Celler J, Phillips RA, Wu GE: High frequency of normal DJH joints in B-cell progenitors in severe combined immunodeficiency mice. *J Exp Med* 178:1007–1016, 1993
 17. Fox CJ, Danska JS: IL-4 expression at the onset of islet inflammation predicts nondestructive insulinitis in nonobese diabetic mice. *J Immunol* 158:2414–2424, 1997
 18. Fox CJ, Danska JS: Independent genetic regulation of T-cell and antigen-presenting cell participation in autoimmune islet inflammation. *Diabetes* 47:331–338, 1998
 19. Von Boehmer H, Schubiger K: Thymocytes appear to ignore class I major histocompatibility complex antigens expressed on thymus epithelial cells. *Eur J Immunol* 14:1048–1052, 1984
 20. Kitamura D, Roes J, Kuhn R, Rajewsky K: A B-cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. *Nature* 350:423–426, 1991
 21. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, McKenna S, Mobraaten L, Rajan TV, Greiner DL, Leiter EH: Multiple defects in innate and adaptive immunologic function in NOD/LtSz-*scid* mice. *J Immunol* 154:180–191, 1995
 22. Kawamoto H, Ohmura K, Katsura Y: Presence of progenitors restricted to T B, or myeloid lineage, but absence of multipotent stem cells, in the murine fetal thymus. *J Immunol* 161:3799–3802, 1998
 23. Carroll AM, Hardy RR, Bosma MJ: Occurrence of mature B (Ig⁺ and B220⁺) and T (CD3⁺) lymphocytes in *scid* mice. *J Immunol* 17:1467–1471, 1989
 24. Hendrickson EA, Schissel MS, Weaver DT: Wild-type V(D)J recombination in *scid* pre-B-cells. *Mol Cell Biol* 10:5397–5407, 1990
 25. Kotloff DB, Bosma MJ, Ruetsch NR: V(D)J recombination in peritoneal B-cells of leaky *scid* mice. *J Exp Med* 178:1981–1994, 1993
 26. Schuler W, Weiler LJ, Schuler A, Phillips RA, Rosenberg N, Mak TW, Kearney JF, Perry RP, Bosma MJ: Rearrangement of antigen receptor genes is defective in mice with severe combined immune deficiency. *Cell* 46:963–972, 1986
 27. Serreze DV, Fleming SA, Chapman HD, Richard SD, Leiter EH, Tisch RM: B lymphocytes are critical antigen-presenting cells for the initiation of T-cell-mediated autoimmune diabetes in nonobese diabetic mice. *J Immunol* 161:3912–3918, 1998
 28. Yang M, Charlton B, Gautam AM: Development of insulinitis and diabetes in B-cell-deficient NOD mice. *J Autoimmun* 10:257–260, 1997
 29. Kanagawa O, Xu G, Tevaarwerk A, Vaupel BA: Protection of nonobese diabetic mice from diabetes by gene(s) closely linked to IFN-gamma receptor loci. *J Immunol* 164:3919–3923, 2000
 30. Andersson A, Forsgren S, Soderstrom A, Holmberg D: Monoclonal, natural antibodies prevent development of diabetes in the non-obese diabetic (NOD) mouse. *J Autoimmun* 4:733–742, 1991
 31. Yang X, Brunham RC: Gene knockout B-cell-deficient mice demonstrate that B-cells play an important role in the initiation of T-cell responses to *Chlamydia trachomatis* (mouse pneumonitis) lung infection. *J Immunol* 161:1439–1446, 1998
 32. Vordermeier HM, Venkataprasad N, Harris DP, Ivanyi J: Increase of tuberculous infection in the organs of B-cell-deficient mice. *Clin Exp Immunol* 106:312–316, 1996
 33. Matsuzaki G, Vordermeier HM, Hashimoto A, Nomoto K, Ivanyi J: The role of B-cells in the establishment of T-cell response in mice infected with an intracellular bacteria: *Listeria monocytogenes*. *Cell Immunol* 194:178–185, 1999
 34. Williams GS, Oxenius A, Hengartner H, Benoist C, Mathis D: CD4⁺ T-cell responses in mice lacking MHC class II molecules specifically on B-cells. *Eur J Immunol* 28:3763–3772, 1998
 35. Ridgway WM, Vasso M, Lanctot A, Garvey C, Fathman CG: Breaking self-tolerance in nonobese diabetic mice. *J Exp Med* 183:1657–1662, 1996
 36. Leijon K, Hammarstrom B, Holmberg D: Non-obese diabetic (NOD) mice display enhanced immune responses and prolonged survival of lymphoid cells. *Int Immunol* 6:339–345, 1994
 37. Penha-Goncalves C, Leijon K, Persson L, Holmberg D: Type 1 diabetes and the control of dexamethazone-induced apoptosis in mice maps to the same region on chromosome 6. *Genomics* 28:398–404, 1995
 38. Colucci F, Cilio CM, Lejon K, Goncalves CP, Bergman ML, Holmberg D: Programmed cell death in the pathogenesis of murine IDDM: resistance to apoptosis induced in lymphocytes by cyclophosphamide. *J Autoimmun* 9:271–276, 1996
 39. Colucci F, Bergman ML, Penha-Goncalves C, Cilio CM, Holmberg D: Apoptosis resistance of nonobese diabetic peripheral lymphocytes linked to the *Idd5* diabetes susceptibility region. *Proc Natl Acad Sci U S A* 94:8670–8674, 1997
 40. Guberski DL, Butler L, Kastern W, Like AA: Genetic studies in inbred BB/Wor rats: analysis of progeny produced by crossing lymphopenic diabetes-prone rats with nonlymphopenic diabetic rats. *Diabetes* 38:887–893, 1989
 41. Markholst H, Eastman S, Wilson D, Andreasen BE, Lernmark A: Diabetes segregates as a single locus in crosses between inbred BB rats prone or resistant to diabetes. *J Exp Med* 174:297–300, 1991
 42. Rossini AA, Faustman D, Woda BA, Like AA, Szymanski I, Mordes JP: Lymphocyte transfusions prevent diabetes in the Bio-Breeding/Worcester rat. *J Clin Invest* 74:39–46, 1984
 43. Rossini AA, Mordes JP, Greiner DL, Nakano K, Appel MC, Handler ES: Spleen cell transfusion in the Bio-Breeding/Worcester rat: prevention of diabetes, major histocompatibility complex restriction, and long-term persistence of transfused cells. *J Clin Invest* 77:1399–1401, 1986
 44. Crisa L, Mordes JP, Rossini AA: Autoimmune diabetes mellitus in the BB rat. *Diabete Metab Rev* 8:4–37, 1992
 45. Rossini AA, Slavina S, Woda BA, Geisberg M, Like AA, Mordes JP: Total lymphoid irradiation prevents diabetes mellitus in the Bio-Breeding/Worcester (BB/W) rat. *Diabetes* 33:543–547, 1984
 46. Ramanathan S, Poussier P: T-cell reconstitution of BB/W rats after the initiation of insulinitis precipitates the onset of diabetes. *J Immunol* 162:5134–5142, 1999
 47. Harada M, Makino S: Promotion of spontaneous diabetes in non-obese diabetes-prone mice by cyclophosphamide. *Diabetologia* 27:604–606, 1984
 48. Charlton B, Bacelj A, Slattery RM, Mandel TE: Cyclophosphamide-induced diabetes in NOD/WEHI mice: evidence for suppression in spontaneous autoimmune diabetes mellitus. *Diabetes* 38:441–447, 1989
 49. Inaba K, Witmer-Pack M, Inaba M, Hathcock KS, Sakuta H, Azuma M, Yagita H, Okumura K, Linsley PS, Ikehara S, Muramatsu S, Hodes RJ, Steinman RM: The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. *J Exp Med* 180:1849–1860, 1994
 50. Cassell DJ, Schwartz RH: A quantitative analysis of antigen-presenting cell function: activated B-cells stimulate naive CD4 T-cells but are inferior to dendritic cells in providing costimulation. *J Exp Med* 180:1829–1840, 1994

51. Jun HS, Santamaria P, Lim HW, Zhang ML, Yoon JW: Absolute requirement of macrophages for the development and activation of β -cell cytotoxic CD8⁺ T-cells in T-cell receptor transgenic NOD mice. *Diabetes* 48:34–42, 1999
52. Lee KU, Amano K, Yoon JY: Evidence for initial involvement of macrophage in development of insulinitis in NOD mice. *Diabetes* 37:989–991, 1988
53. Lo D, Reilly CR, Scott B, Liblau R, McDevitt H, Burky L: Antigen-presenting cells in adoptively transferred and spontaneous autoimmune diabetes. *Eur J Immunol* 23:1693–1698, 1993
54. Jansen A, Homo-Delarche F, Hooijkaas H, Leenen PJ, Dardenne M, Drexhage HA: Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of insulinitis and β -cell destruction in NOD mice. *Diabetes* 43:667–675, 1994
55. Dahlen E, Dawe K, Ohlsson L, Hedlund G: Dendritic cells and macrophages are the first and major producers of TNF-alpha in pancreatic islets in the nonobese diabetic mouse. *J Immunol* 160:3585–3593, 1998
56. Hutchings P, Rosen H, O'Reilly O, Simpson E, Gordon S, Cooke A: Transfer of diabetes in mice prevented by blockade of adhesion-promoting receptor on macrophages. *Nature* 639–642, 1990
57. Jun HS, Yoon CS, Zbytnuik L, van Rooijen N, Yoon JW: The role of macrophages in T-cell-mediated autoimmune diabetes in nonobese diabetic mice. *J Exp Med* 189:347–358, 1999
58. Chung J-H, Jun H-S, Kang Y, Hirasawa K, Lee B-R, van Rooijen N, Yoon J-W: Role of macrophages and macrophage-derived cytokines in the pathogenesis of Kilham rat virus-induced autoimmune diabetes in diabetes-resistant BioBreeding rats. *J Immunol* 159:466–471, 1997
59. Ludewig B, Odermatt B, Landmann S, Hengartner H, Zinkernagel RM: Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue. *J Exp Med* 188:1493–1501, 1998